Larimar Therapeutics, Inc. (LRMR)
- Previous Close
2.1000 - Open
2.1700 - Bid 2.1100 x 200
- Ask 2.1900 x 100
- Day's Range
2.0300 - 2.2091 - 52 Week Range
1.6100 - 11.2000 - Volume
1,592,118 - Avg. Volume
957,019 - Market Cap (intraday)
138.941M - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5100 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.04
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
larimartx.comRecent News: LRMR
View MorePerformance Overview: LRMR
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LRMR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LRMR
View MoreValuation Measures
Market Cap
138.94M
Enterprise Value
-13.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.96
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.47%
Return on Equity (ttm)
-50.77%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-95.23M
Diluted EPS (ttm)
-1.5100
Balance Sheet and Cash Flow
Total Cash (mrq)
157.53M
Total Debt/Equity (mrq)
3.37%
Levered Free Cash Flow (ttm)
-52.86M